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Abstract
Background: Impaired glucose regulation (IGR) is associated with detrimental cardiovascular outcomes
such as cardiovascular disease risk factors (CVD risk factors) or intima-media thickness (IMT). Our aim
was to examine whether these associations are mediated by body mass index (BMI), waist circumference
(waist) or fasting serum insulin (insulin) in a population in the African region.
Methods: Major CVD risk factors (systolic blood pressure, smoking, LDL-cholesterol, HDL-cholesterol,)
were measured in a random sample of adults aged 25–64 in the Seychelles (n = 1255, participation rate:
80.2%).
According to the criteria of the American Diabetes Association, IGR was divided in four ordered
categories: 1) normal fasting glucose (NFG), 2) impaired fasting glucose (IFG) and normal glucose tolerance
(IFG/NGT), 3) IFG and impaired glucose tolerance (IFG/IGT), and 4) diabetes mellitus (DM). Carotid and
femoral IMT was assessed by ultrasound (n = 496).
Results: Age-adjusted levels of the major CVD risk factors worsened gradually across IGR categories
(NFG < IFG/NGT < IFG/IGT < DM), particularly HDL-cholesterol and blood pressure (p for trend <
0.001). These relationships were marginally attenuated upon further adjustment for waist, BMI or insulin
(whether considered alone or combined) and most of these relationships remained significant. With
regards to IMT, the association was null with IFG/NGT, weak with IFG/IGT and stronger with DM (all
more markedly at femoral than carotid levels). The associations between IMT and IFG/IGT or DM
(adjusted by age and major CVD risk factors) decreased only marginally upon further adjustment for BMI,
waist or insulin. Further adjustment for family history of diabetes did not alter the results.
Conclusion: We found graded relationships between IGR categories and both major CVD risk factors
and carotid/femoral IMT. These relationships were only partly accounted for by BMI, waist and insulin. This
suggests that increased CVD-risk associated with IGR is also mediated by factors other than the
considered markers of adiposity and insulin resistance. The results also imply that IGR and associated
major CVD risk factors should be systematically screened and appropriately managed.
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Worldwide, the number of persons with diabetes mellitus
(DM) is expected to double in the next 25 years and to
affect more than 350 million individuals by 2030 [1].
Accordingly, there is a growing interest in identifying indi-
viduals in stages preceding overt DM in order to poten-
tially prevent the occurrence of DM and associated
complications. The majority of complications of DM are
related to cardiovascular disease (CVD) and it is therefore
important to assess whether pre-diabetes stages are also
associated with detrimental vascular outcomes [2].
Pre-diabetes has been first described by the World Health
Organization in 1980 as impaired glucose tolerance (IGT)
[3]. In order to avoid the time-consuming and somewhat
cumbersome measurement of 2-hour postload glucose
concentrations (2hBG), the American Diabetes Associa-
tion (ADA) proposed in 1997 to identify pre-diabetes as
impaired fasting glucose (IFG), which relies on one fast-
ing measurement only. In 2004, the ADA lowered the cut-
off point for IFG from 6.1 to 5.6 mmol/l [4]. It has been
demonstrated that both IFG and IGT are risk factors for
the subsequent development of both DM [5,6] and CVD
[2,5,7]. However, the respective prognostic values of IFG
and IGT to predict DM and CVD risk are still controversial
[5,8-11].
Because they measure different aspects of glucose metab-
olism, IFG and IGT have different underlying physiologi-
cal and clinical significance with respect to insulin
sensitivity and secretion [12-14]. Subsequently, these two
categories of impairment of glucose regulation (IGR) may
differently relate to CVD risk factors. However, both IFG
and IGT are strongly associated with excess body weight,
which in turn is associated with insulin resistance. Hence,
the relationship between IGR categories and CVD risk fac-
tors or CVD outcomes may be mediated by such markers
of adiposity or insulin resistance.
Intima-media thickness (IMT) of peripheral arteries (par-
ticularly carotid IMT) can be regarded as a cardiovascular
risk factor since it is an independent predictor of CVD
morbidity and mortality [15]. However, IMT also meas-
ures organic vascular changes -atherosclerosis- [16] and it
is therefore also increasingly used as a proxy of CVD out-
comes [17,18].
In this study we compared the association between IGR
categories (IFG, IGT and DM) and both 1) major CVD risk
factors (blood pressure, smoking, LDL-cholesterol, HDL-
cholesterol) and 2) IMT (carotid and femoral IMT). We
hypothesized that these associations would be substan-
tially explained by markers of adiposity and fasting serum
insulin concentration, hence that these relationships
would not remain significant upon adjustment for these
markers. We examined these relationships in a sample
representative of the general population of the Seychelles,
a rapidly developing country in health transition in the
African region. The distribution of the main cardiovascu-
lar risk factors, pre-diabetes and diabetes in this popula-
tion has been described previously [19-21].
Methods
Population
The Republic of Seychelles consists of over 100 islands
located in the Indian Ocean about 2000 km east of Kenya
and 2000 km north of Mauritius, in the African region.
Approximately 90% of the population lives on the main
island (Mahé) and most of the remaining population
resides on two nearby islands. Although intermarriage has
blurred racial differences in many Seychellois, it can be
considered that approximately two thirds of the popula-
tion is of predominantly African descent, 15% is of pre-
dominantly Caucasian, Indian or Chinese descent, and a
fifth is mixed between these groups. The population can
be considered as fairly urbanized in view of the high den-
sity of the population and the facts that a large proportion
of the population commutes to the capital for work and
three quarters of workers are employed in services [22,23].
The national gross domestic product per capita, in real
terms, rose from US$ 2927 in 1980 to US$ 5239 in 2004
[24], reflecting booming tourism and fishing industries.
All deaths are registered in Seychelles and vital statistics
indicate a life expectancy at birth of 69 years in men and
76 years in women. In Seychelles, cardiovascular disease
and AIDS currently account for 38% and 1% of all deaths,
respectively [25].
Participants
A population-based survey for cardiovascular risk factors
was conducted in 2004 under the auspices of the Ministry
of Health of the Republic of Seychelles. The sampling
frame consisted of a sex- and age- stratified random sam-
ple of the population aged 25–64. Eligible individuals
were selected from a computerized database of the entire
population derived from the population census carried
out in 2002, thereafter updated by civil authorities. Partic-
ipants were invited to participate through a personal letter
requesting them to attend a survey center on a specified
day, fasting, between 7:30 and 11:00 am. Individuals were
free to participate and gave written informed consent. The
survey was approved by the Ministry of Health following
technical and ethical reviews.
Categories of impaired glucose regulation
Venous blood glucose (FBG) was measured with a
Cholestec LDX, a point-of-care analyzer which is a reliable
alternative to conventional laboratory devices [26]. The
Cholestec instrument separates blood cells from plasma
and measurements are therefore made on plasma. If glu-Page 2 of 10
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out a few minutes later on capillary blood (Bayer, Ascentia
Elite [27]) and the mean of both readings was used. Of
note, the Ascentia Elite automatically adjusts its glucose
readings to plasma values. The difference between the first
FBG measurement (Cholestec) and the second FBG meas-
urement (Ascentia Elite) was as small as -0.15 mmol/l.
Individuals who were not aware of DM and with FBG ≥
5.6 mmol/l and < 7 mmol/l were submitted to an oral glu-
cose tolerance test (OGTT) using a meal of 75 g glucose
dissolved in 300 ml water and capillary glucose (Ascentia
Elite) was measured 120 min later (2hBG). Categories of
impaired glucose regulation (IGR) were based on the new
criteria of the ADA [4]. DM was defined as FBG ≥ 7.0
mmol/l, 2hBG ≥ 11.1 mmol/l, or a current history of anti-
diabetic medication. IFG refers to FBG of 5.6–6.9 mmol/
l. IGT was defined as FBG < 7.0 mmol/l and 2hBG of 7.8–
11.0 mmol/l. Normal glucose tolerance (NGT) was
defined as 2hBG < 7.8 mmol/l. NFG refers to FBG values
< 5.6 mmol/l.
Covariates
A structured questionnaire was administered to partici-
pants by trained survey officers. Family history of DM was
defined as reported DM among a first degree parent or sib-
ling. Weight was measured with an electronic scale at 0.2
kg precision (Seca, Hamburg, Germany), height with a
fixed stadiometer at 0.5 cm precision (Seca). BMI was cal-
culated as weight divided by height squared (kg/m2).
Waist circumference (waist) was measured at the level of
the umbilicus in standing position, with individuals in
light garments. Blood pressure (BP) refers to the average
of the second and third of three measurements (mercury
sphygmomanometer, cuff size adjusted to arm circumfer-
ence). Smoking was defined as current smoking of at least
1 cigarette/day.
Serum was obtained within 2 hours of blood collection
and immediately frozen to -20°C. Fasting serum insulin
(insulin) was measured using commercial RIA kits
(LINCO Research Inc, Missouri, USA). Blood lipids were
measured using standard methods (Hitachi 917 instru-
ment and Roche reagents). In this paper, we refer to CVD
risk factors to designate major CVD risk factors, i.e. systo-
lic blood pressure, smoking, LDL-cholesterol, and HDL-
cholesterol. We used insulin as our primary marker of
insulin resistance. We preferred insulin (to HOMA
(homeostasis model assessment of insulin resistance) as
the former is directly measured and the latter is calculated
and includes a variable (fasting blood glucose) that is also
used to define categories of IGR in our analyses.
Ultrasonography
High-resolution B-mode ultrasonography was conducted
in all participants above 45 years seen during a 17-week
period (n = 496) as well as in a randomly selected sample
(18%, n = 57) of the participants aged 35–44 years. We
restricted the investigation to this age range because older
persons are more likely to have atherosclerosis. Carotid
intima-media thickness is a well-established surrogate
marker for atherosclerotic disease that is increasingly used
in observational and interventional studies [28]. All the
scans and image measurements were carried out by the
same investigator (P.Y.) who was blinded to the risk factor
status of the participants. We used a portable ultrasound
system (General Electric LogiqBook) connected with a 6–
10 MHz linear array transducer. The system was equipped
with a software (M'ATH, ICN-metric, Paris, France) to per-
form semi-automatic measures of intima-media thickness
(IMT) on frame [29]. IMT was measured on the far wall of
both the right and left common carotid and femoral arter-
ies over a length of 1 cm on a reference site located 2 cm
below the bifurcation. The measurements on the left and
right arteries were averaged to obtain a single mean value
at carotid and femoral levels and all four measurements
were averaged to obtain a combined value for all four
arteries. The far wall was used because of higher reproduc-
ibility and possible overestimation of the IMT of the near
wall [30]. To examine the reproducibility, we made a
repeat investigation in 20 randomly selected participants
within few week intervals. For carotid IMT, the coefficient
of variation was 4.8%, which is similar to findings in
other studies [31]. For femoral IMT, the coefficient of var-
iation was 9.2%.
Statistical analysis
Prevalence estimates were standardized to the age distri-
bution of the WHO [32]. We tested differences in means
(± standard errors, SE) of CVD risk factors across catego-
ries of IRG with the chi-square test and the t-test, respec-
tively. One-way analysis of variance was used to compare
categorical variables between the four groups. Trends were
calculated with the Stata-command "nptrend" (by Cuzick,
1985 and Altman, 1991). The associations between IFG/
NGT, IFG/IGT and DM and risk factors were analyzed
with multivariate linear regression. Models were adjusted
for age, sex, BMI, waist, insulin, systolic BP, LDL-choles-
terol, HDL-cholesterol and smoking status. We did not
include triglyceride in the main multivariate analyses
because: i) the independent role of triglycerides remains
controversial; ii) triglyceride is generally not included as a
major risk factor in CVD risk models; iii) triglyceride is
strongly associated with resistance insulin and/or HDL
cholesterol, as we have shown in the same data [20]. Anal-
yses were performed with Stata 8.2 and P values < 0.05
were considered significant.
Results
1,255 persons (568 men and 568 women) participated
out of 1,565 eligible individuals, a participation rate ofPage 3 of 10
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NGT (11.6%), IFG/IGT (10.4%) or DM (11.5%). How-
ever, while the prevalence did not differ by gender for DM
(11.0% in men and 12.1% in women) and IFG/IGT
(11.2% in men and 9.6% in women), the prevalence of
IFG/NGT was higher in men than in women (17.6% vs.
5.7%, p < 0.001). The overall age-adjusted prevalence (±
SE) of family history of diabetes was 30.0 ± 1.3% (men:
26.6 ± 1.9, women: 33.2 ± 1.8). The age-adjusted preva-
lence of family history of diabetes tended to increase
across categories of NFG (26.6 ± 1.6%, men: 22.0 ± 2.3,
women: 30.4 ± 2.2), IFG/NGT (28.9 ± 3.7, men: 23.3 ±
4.6, women: 27.5 ± 6.6), IFG/IGT (36.5 ± 4.0, men: 33.1
± 5.5, women: 40.6 ± 5.6), and DM (44.0 ± 3.7, men: 40.5
± 5.5, women: 47.5 ± 5.0).
Table 1 shows the distribution of anthropometric, clinical
and ultrasound results by categories of IGR and by sex.
The results are standardized for age using 10-year age cat-
egories. Mean BMI, waist and insulin were higher in
women than in men in almost all IGR categories while
mean triglycerides concentration was lower in women
Table 1: Distribution of selected clinical and metabolic factors across categories of impaired glucose regulation
Variable NFG IFG/NGT IFG/IGT DM z-trend*
Men
Clinical and metabolic data (n) 316 98 73 81 8.1
Age (years) 42.5 ± 0.6 45.1 ± 0.9 49.3 ± 1.1 52.7 ± 1.0 5.9
Body mass index (kg/m2) 24.6 ± 0.3 26.6 ± 0.4 26.6 ± 0.5 27.7 ± 0.6 8.2
Waist circumference (cm) 85.8 ± 0.6 92.5 ± 1.0 93.0 ± 1.4 97.5 ± 1.3 7.8
Serum fasting insulin (pmol/l) 10.8 ± 0.4 14.2 ± 0.8 19.8 ± 2.4 20.9 ± 2.1 6.9
Triglycerides (mmol/l) 0.97 ± 0.03 1.20 ± 0.07 1.56 ± 0.19 1.76 ± 0.17 2.5
LDL cholesterol (mmol/l) 3.42 ± 0.07 3.60 ± 0.13 3.83 ± 0.14 3.75 ± 0.17 -3.8
HDL cholesterol (mmol/l) 1.42 ± 0.03 1.29 ± 0.05 1.27 ± 0.06 1.20 ± 0.05 8.0
Systolic blood pressure (mmHg) 127 ± 0.9 132 ± 1.6 137 ± 1.9 145 ± 2.3
Mean intima-media thickness (n) 104 46 48 50 2.4
Carotid (mm) 0.72 ± 0.01 0.71 ± 0.02 0.78 ± 0.03 0.75 ± 0.02 5.2
Femoral (mm) 0.93 ± 0.06 0.92 ± 0.09 1.20 ± 0.10 1.41 ± 0.13 4.9
Total (mm) 0.76 ± 0.02 0.82 ± 0.04 0.90 ± 0.03 1.04 ± 0.04
Women
Clinical and metabolic data (n) 460 47 77 103
Age (years) 41.4 ± 0.5 52.1 ± 1.4 50.1 ± 1.0 54.4 ± 0.8 11.9
Body mass index (kg/m2) 27.1 ± 0.3 31.5 ± 0.9 31.8 ± 0.7 31.8 ± 0.5 8.4
Waist circumference (cm) 86.7 ± 0.6 100.1 ± 2.1 97.4 ± 1.4 101.5 ± 1.1 10.7
Serum fasting insulin (pmol/l) 13.8 ± 0.4 21.1 ± 1.9 19.4 ± 1.4 25.4 ± 2.1 8.4
Triglycerides (mmol/l) 0.82 ± 0.02 1.07 ± 0.08 1.10 ± 0.1 1.35 ± 0.08 8.8
LDL cholesterol (mmol/l) 3.44 ± 0.05 4.11 ± 0.19 3.81 ± 0.14 4.20 ± 0.14 5.8
HDL cholesterol (mmol/l) 1.40 ± 0.02 1.32 ± 0.05 1.28 ± 0.0 1.21 ± 0.04 -5.0
Systolic blood pressure (mmHg) 120 ± 0.7 137 ± 3.8 134 ± 2.1 139 ± 1.9 10.3
Mean intima-media thickness (n) 155 30 45 76
Carotid (mm) 0.69 ± 0.01 0.75 ± 0.02 0.74 ± 0.04 0.84 ± 0.03 5.6
Femoral (mm) 0.71 ± 0.03 0.88 ± 0.09 0.84 ± 0.06 1.16 ± 0.07 6.5
Total (mm) 0.76 ± 0.02 0.82 ± 0.04 0.90 ± 0.03 1.04 ± 0.04 7.4
Overall
Clinical and metabolic data (n) 776 145 150 184
Age (years) 41.8 ± 0.4 47.4 ± 0.8 49.7 ± 0.7 53.7 ± 0.6 14.3
Body mass index (kg/m2) 26.0 ± 0.2 27.8 ± 0.4 29.0 ± 0.5 29.7 ± 0.4 9.5
Waist circumference (cm) 86.3 ± 0.4 94.3 ± 1.0 95.1 ± 1.0 99.5 ± 0.9 13.4
Serum fasting insulin (pmol/l) 12.5 ± 0.3 15.9 ± 0.8 19.6 ± 1.4 23.3 ± 1.5 11.1
Triglycerides (mmol/l) 0.89 ± 0.02 1.17 ± 0.05 1.35 ± 0.10 1.55 ± 0.09 11.2
LDL cholesterol (mmol/l) 3.43 ± 0.04 3.73 ± 0.11 3.82 ± 0.10 3.98 ± 0.11 5.8
HDL cholesterol (mmol/l) 1.41 ± 0.02 1.30 ± 0.04 1.27 ± 0.04 1.21 ± 0.03 -6.5
Systolic blood pressure (mmHg) 123 ± 0.6 134 ± 1.6 136 ± 1.4 142 ± 1.5 13.1
Mean intima-media thickness (n) 258 76 93 126
Carotid (mm) 0.71 ± 0.01 0.72 ± 0.01 0.76 ± 0.02 0.80 ± 0.02 5.9
Femoral (mm) 0.81 ± 0.03 0.91 ± 0.07 1.04 ± 0.06 1.27 ± 0.07 8.3
Total (mm) 0.76 ± 0.02 0.82 ± 0.04 0.90 ± 0.03 1.04 ± 0.04 8.7
Values displayed are age-standardized means ± standard error.
*z-value for trend; all corresponding p-values < 0.01.Page 4 of 10
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no gender difference was found in HDL cholesterol, LDL
cholesterol and BP across IGR categories. Interestingly,
waist tended to increase more gradually along IGR catego-
ries than BMI resulting in a larger z-value for the trend test
for waist than for BMI. Also, waist tended to increase
between the IFG/IGT and DM categories while BMI did
not. However, the proportional increase between NGT
and DM categories was almost identical for BMI and waist
for both men (~13%) and women (~17%). Tests for trend
were significant for all variables (we show the z-values for
the tests, i.e. the log of the p value, since all p-values are <
0.01). P values for all trends tended to be stronger in
women than in men.
Table 2 shows the multivariate association between CVD
risk factors and categories of IGR upon incremental
adjustment for covariates related to adiposity (BMI and
waist) and insulin resistance. All models are adjusted for
sex and age, since age is strongly associated with IGR and
the considered CVD risk factors (hence an important con-
founding factor). Incremental adjustment for BMI, waist
and insulin allows disentangling confounding effects by
these variables since adiposity and/or insulin resistance
are known to be associated both with most of the consid-
ered CVD risk factors and IGR. Adjustment for BMI or
waist reduced the magnitude of the regression coefficients
between CVD risk factors and IGR only slightly. This
attenuation effect tended to be larger with waist than BMI.
The association between CVD risk factors and IGR catego-
ries was also slightly attenuated upon adjustment of insu-
lin. Attenuation of the relationship between CVD risk
factors and IGR was similar upon adjustment of BMI,
waist or insulin. Concurrent adjustment for all three
markers (BMI, waist and insulin) produced the smallest
coefficients for all CVD risk factors in virtually all IGR cat-
egories. However, the attenuation of the relation between
CVD risk factors and IGR categories was only marginally
larger upon adjustment with all three adiposity/insulin
resistance markers (BMI, waist, insulin) as compared to
adjustment for any of these markers. This suggests that
any of these three markers similarly reflected a common
underlying mechanism.
The association between CVD risk factors and IGR catego-
ries increased generally fairly monotonically over increas-
ing IGR categories, with as much an increase in the
regression coefficients between the IFG/NGT and IFG/IGT
Table 2: Associations between categories of impaired glucose regulation and selected cardio-metabolic risk factors
IFG/NGT IFG/IGT DM
Adjustment in addition to age and sex Coef. SE p Coef. SE p Coef. SE p
Triglycerides (mmol/l)
None 0.19 0.07 0.01 0.39 0.07 0.00 0.59 0.07 0.00
BMI 0.14 0.07 0.05 0.33 0.07 0.00 0.52 0.07 0.00
Waist 0.10 0.07 ns 0.31 0.07 0.00 0.46 0.07 0.00
Insulin 0.15 0.07 0.03 0.29 0.07 0.00 0.48 0.08 0.00
BMI, Waist, Insulin 0.09 0.07 ns 0.25 0.07 0.00 0.41 0.08 0.00
Low-density lipoprotein cholesterol (mmol/l)
None 0.26 0.11 0.02 0.29 0.12 0.02 0.39 0.12 0.00
BMI 0.19 0.11 0.09 0.21 0.12 0.07 0.30 0.12 0.01
Waist 0.15 0.11 ns 0.19 0.12 ns 0.24 0.12 0.04
Insulin 0.22 0.11 0.05 0.20 0.12 ns 0.23 0.12 0.06
BMI, Waist, Insulin 0.15 0.11 ns 0.15 0.12 ns 0.16 0.12 ns
High-density lipoprotein cholesterol (mmol/l)
None -0.14 0.04 0.00 -0.19 0.05 0.00 -0.27 0.05 0.00
BMI -0.08 0.04 0.05 -0.12 0.04 0.01 -0.19 0.04 0.00
Waist -0.06 0.04 ns -0.11 0.04 0.02 -0.16 0.04 0.00
Insulin -0.11 0.04 0.01 -0.14 0.05 0.00 -0.20 0.05 0.00
BMI, Waist, Insulin -0.05 0.04 ns -0.09 0.04 0.04 -0.14 0.05 0.00
Systolic blood pressure (mmHg)
None 5.43 1.49 0.00 7.02 1.56 0.00 10.82 1.54 0.00
BMI 4.15 1.48 0.01 5.55 1.56 0.00 9.14 1.54 0.00
Waist 3.67 1.49 0.01 5.39 1.55 0.00 8.38 1.56 0.00
Insulin 4.57 1.50 0.00 5.72 1.59 0.00 9.48 1.64 0.00
BMI, Waist, Insulin 3.45 1.50 0.02 4.87 1.58 0.00 8.42 1.64 0.00
ns: p ≥ 0.10.
NFG: normal fasting glucose; IFG: impaired fasting glucose; NGT: normal glucose tolerance; IGT: impaired glucose tolerance; DM: diabetes mellitus; 
BMI: body mass index; waist: waist circumference; insulin: serum fasting insulin.Page 5 of 10
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the considered CVD risk factors were associated with all
three IGR categories, except for CRP and IFG/NGT. How-
ever, a few associations were no longer significant upon
full adjustment for adiposity and insulin resistance mark-
ers (BMI, waist, insulin). For DM, the associations
remained significant for all CVD risk factors except LDL-
cholesterol. For IFG/IGT, the associations remained sig-
nificant for all CVD risk factors except LDL-cholesterol
and CRP. For IFG/NGT, the associations remained for trig-
lyceride and systolic BP but not for LDL-cholesterol, HDL-
cholesterol and CRP. The association of IGR with BP was
similar whether based on diastolic or systolic BP (results
not shown).
Family history of diabetes was associated with IFG/IGT
and DM, but not with IFG/NGT. Adjustment for family
history of DM in addition to age, sex, BMI, waist and insu-
lin had virtually no impact on the associations (i.e. regres-
sion coefficients) between CVD risk factors and IGR
categories (results not shown). This suggests that the rela-
tionships between CVD RF and IGR are not mediated by
family history. In addition, IGR categories were associ-
ated, in adjusted models, with apo B and CRP but not
with apo A1 and cystatin C (results not shown).
In Figure 1, we considered carotid/femoral IMT as a
marker of atherosclerosis, hence as a CVD outcome. All
associations between IFG/NGT and IMT were not statisti-
cally significant and are thus not shown. The analysis
examines whether IGR categories predict IMT independ-
ently of age and CVD risk factors and whether an associa-
tion, if any, would be sensitive to further adjustment of
markers of adiposity or insulin resistance (BMI, waist, and
insulin). The data show no association with IFG/NGT, a
weak association with IFG/IGT, and a stronger association
with DM. All these associations were stronger at femoral
than carotid levels.
Adjustment for CVD risk factors attenuated the relation-
ship between IGR categories and IMT, which suggests that
a substantial part of the effect of IGR on IMT is mediated
by BP, LDL-cholesterol, HDL-cholesterol and smoking
status. Further adjustment for triglyceride, in addition to
the considered major CVD risk factors, left the regression
coefficients virtually unchanged (results not shown). Fur-
ther adjustment for BMI, waist and insulin, whether con-
sidered separately or in combination, further reduced
these relationships only marginally (as assessed by the
further small relative decrease in the age and CVD risk fac-
tors adjusted regression coefficients). The associations
between DM and either femoral IMT or total IMT (i.e.
femoral + carotid) remained significant upon full adjust-
ment for age, sex, CVD risk factors and adiposity and insu-
lin resistance markers. This suggests that IGR (particularly
DM) is related to IMT through mechanisms other than
those conveyed by these factors.
Using HOMA instead of insulin for analyses shown in
Table 2 and Figure 1 resulted in slightly different regres-
sion coefficients for HOMA than insulin in some
instances although results were almost identical in many
instances (results not shown).
Discussion
We found that pre-diabetes was associated with worsened
levels of several major CVD risk factors as well as with
increased carotid and femoral IMT independently of
markers of adiposity (waist and BMI) or a marker of insu-
lin resistance (insulin).
Associations between intima-media thickness (IMT) and cate-gories of impaired glucose metabolism upon increme tal adjustment for covariates (regr ssion coefficients with their standard err s)Figure 1
Associations between intima-media thickness (IMT) 
and categories of impaired glucose metabolism upon 
incremental adjustment for covariates (regression 
coefficients with their standard errors). Panel A: 
impaired fasting glucose/impaired glucose tolerance 
(IFG/IGT); Panel B: diabetes (DM). * p: 0.05–0.09. ** p 
< 0.05. All associations between impaired fasting glucose/
normal glucose tolerance (IFG/NGT) and IMT were statisti-
cally not significant and are thus not shown. None: no adjust-
ment; RF: major risk factors (low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, systolic 
blood pressure, smoking); BMI: body mass index; WC: waist 
circumference; I: serum fasting insulin.
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in explaining the relationships between IGR and the
major CVD risk factors deserves several comments. First,
we observed that BMI, waist or insulin attenuated the rela-
tionship between IGR categories to a fairly similar small
extent and that adjusting for these factors altogether did
not add substantial adjustment as compared to adjust-
ment based on any of the three markers alone. This sug-
gests that these three markers represent a same
dimension/mechanism (e.g. insulin resistance) and that
none of these markers conveys a substantial advantage in
representing this dimension. In our results, waist tended
however to perform slightly better than BMI. An advan-
tage of waist over BMI has been found in some studies
[33], but not all [34]. The fairly similar non-additive effect
of the three considered markers (insulin, BMI, waist) has
practical clinical relevance: BMI (or waist) is much sim-
pler and less expensive to asses as compared to insulin
and BMI (or waist) might be preferred to insulin for risk
stratification, particularly in resource-constrained set-
tings.
Several factors may underlie the smaller than expected
effect of the considered markers (BMI, waist, insulin) on
the relationship between IGR and major CVD risk factors.
First, this may reflect the known fact that only a sub-group
of obese persons are insulin resistant and are at risk for
developing IGR [35] and that obese individuals without
insulin resistance have only marginally increased CVD
risk [35,36]. Second, BMI, waist and insulin may only
imperfectly represent insulin resistance and the effect of
such markers on the relationship between IGR and major
CVD risk factors might have been larger, had we used bet-
ter indicators of insulin resistance. However, better mark-
ers of insulin resistance, such as the euglycemic clamp,
would require complex measurements that are not practi-
cal for epidemiological studies or usual clinical practice.
Third, insulin resistance is a broad description underlying
many different altered physiological factors. In particular,
insulin resistance has been associated with a variety of
pathophysiological effects related to abdominal fat,
including cytokines secretion and inflammatory cell
migration [37]. For instance, the proinflammatory
cytokine TNF-alpha may impair intracellular insulin sign-
aling independently of insulin [37]. BMI, waist and insu-
lin may therefore only poorly correlate with such finer
physiological factors. In particular, insulin may not be a
reliable marker for insulin resistance and subsequent
atherosclerosis [38]. This could particularly be the case in
diabetic persons with depleted insulin secretion (whether
type 1 or type 2 DM). However, a moderate effect of adi-
posity/insulin in explaining the relationship between IGR
and major CVD risk factors is at odds with trials showing
decreased incidence of DM among pre-diabetic persons
who decreased their weight through lifestyle interventions
[39] or through bariatric surgery [40]. A possible explana-
tion underlying this contradiction is that these interven-
tions not only decreased fat mass or insulin but also
improved other factors which may directly improve insu-
lin resistance, e.g. physical activity, nutritional patterns or
secretion/action of several hormones (e.g. incretins).
Similarly to the association with major CVD risk factors,
the relationship between IGR and IMT was only partially
explained by waist, BMI and insulin. In other studies,
carotid IMT was associated with 2hBG but with neither
fasting glycemia nor a insulin sensitivity index [41,42].
Consistent with our results, IMT remained significantly
associated with 2hBG upon adjustment for major CVD
risk factors, waist, BMI and insulin sensitivity index [41].
Interestingly, we found that the relationships between
IGR and IMT tended to be larger at femoral than carotid
levels independently of adjustment. We are not aware of
any other study that has investigated these associations
between IGR and IMT at femoral level. However it was
recently shown that metabolic syndrome components
impacted selectively on IMT at the femoral site: insulin
and triglyceride concentrations were strongly associated
with femoral IMT but not with carotid IMT [18]. These
findings suggest the usefulness of femoral IMT for assess-
ing CVD outcomes [18,43].
In addition, the relationships between IGR and either
major CVD risk factors or IMT may be linked to several
specific mechanisms. It is shown that atherosclerosis is
accelerated by insulin resistance and DM [38]. Atheroscle-
rosis, which also encompasses an inflammatory process
[44], is in turn related to several factors associated with
adiposity and/or insulin resistance. These factors include
numerous adipokines [45] that are released or modulated
by adipose tissue. From another perspective, insulin resist-
ance has also been shown to alter the endothelial func-
tion, which can result in impaired production of NO [46],
reduced blood flow, pro-inflammatory state and pro-
thrombotic state [46,47]. Furthermore, hyperglycemia
can also induce atherosclerosis independently of insulin,
e.g. through glycation of proteins and lipids and by
increasing oxidative stress [44].
We found that IGT was associated with major CVD risk
factors or IMT more strongly than IFG. This different sig-
nificance of IFG and IGT is consistent with other studies
showing a stronger association of IGT than IFG with CVD
risk factors [48] and with IMT [41,49], but not with a
recent prospective study linking CVD and total mortality
at least as strongly with IFG as with IGT [7]. A greater
impact of IGT than IFG may relate to the facts that subjects
with IFG and IGT are more likely to be insulin resistant
whereas subjects with IFG and NGT are more likely to
have insufficient insulin secretion [48,50,51]. It has beenPage 7 of 10
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seems restricted to those individuals with IGR who are
insulin resistant, measured by an insulin sensitivity index
[52] or HOMA-IR [53].
Several limitations of this study need do be considered.
First, we did not perform OGTT in individuals with FBG <
5.6 mmol/l and we could have missed a few cases of DM
and IGT in persons with NFG but pathologically high
2hBG. The number of such cases is however expected to
be small [54]. A second limitation is related to the cross-
sectional nature of our study which precludes defining
causal relationships. Third, we may not have captured
insulin resistance optimally with BMI, waist and insulin.
insulin was shown to relate only moderately with insulin
resistance measured by euglycemic clamp [55]. Also, BMI
and waist are only proxy measures of total adiposity and
intra-abdominal adiposity. Yet, this study adds to the lim-
ited information on the associations between pre diabe-
tes, on the one hand, and CVD risk factors and peripheral
artery IMT, on the other hand. We are not aware of any
previous study that has examined this issue in a popula-
tion in the African region.
Conclusion
Our data show that IGT and to a lesser extent IFG (in addi-
tion to DM) are associated with impaired cardiovascular
conditions (whether risk factors or IMT) and that these
associations are only moderately mediated by markers of
adiposity and insulin resistance. These findings provide
further evidence for increased cardiovascular risk associ-
ated with pre-diabetes (the increased cardiovascular risk
associated with DM is well established) and further stress
the need for early screening and management of pre-dia-
betes.
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